In patients with skin or lung cancer, drugs that inhibit BRAF (v-raf murine sarcoma viral oncogene homolog B) mutations increase the risk for uveitis dramatically compared with conventional ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the ...

Please provide your email address to receive an email when new articles are posted on . Most patients treated with BRAF and MEK inhibitors for histiocytic disorders showed no active disease.

“This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.” “This is the first report of spindle cell sarcoma BRAF ...

The selective BRAF inhibitors vemurafenib (Zelboraf, Roche/Plexxikon) and dabrafenib (Tafinlar, GlaxoSmithKline) have significantly improved survival in patients with BRAF V600–mutant metastatic ...

MIAMI, FLORIDA (EMBARGOED UNTIL MAY 25, 2023, AT 5 P.M. ET) – An early-phase study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine ...

LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...

BRAF and MEK inhibitors are effective in treating resectable melanoma with BRAF V600 mutations, achieving significant pathological responses. The combination therapy significantly improves ...

Another drug is in town for common pediatric brain tumors. Compared with an incumbent offering from Novartis, the newcomer boasts an FDA approval covering a broader patient population. The FDA on ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced new nonclinical data related to plixorafenib (FORE8394; formerly PLX8394), the company's novel, investigational, small-molecule, ...